ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2022
Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 107 citations in OpenAlex.
- Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function.International journal of molecular sciences · 2024Trial
- Prescribing Trajectories in Type 2 Diabetes in the United States, 2019-2024.Diabetes, obesity & metabolism · 2026Article
- Bridging the Digital Divide in Diabetes Care With an AI-Powered Health Coaching Intervention: Qualitative Formative Study.JMIR diabetes · 2026Article
- Article
- Survival and predictors of mortality among adults with type 2 diabetes at a teaching hospital in Ghana: a retrospective cohort study.BMC public health · 2026Article
- Mussel-Bioinspired Edible CaAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Exploring systemic erythropoietin in diabetic retinopathy: Longitudinal associations and biomarker potential in the LANDMark cohort.PloS one · 2026Article
- Factors Associated with Non-Adherence to Blood Glucose Testing Among Non-Hispanic Black and Hispanic Men with a History of Prediabetes in the United States.Patient preference and adherence · 2026Article
- Metaphoric medicine: A retrospective clinical audit of glycaemic outcomes associated with an analogy-based consultation framework for insulin-treated type 2 diabetes mellitus.Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia · 2026Article
- Application study of an artificial intelligence and big data-based personalized chronic disease management model for diabetes patients.Frontiers in public health · 2026Article
- In Pursuit of Person-Centered Medicine: How Do People with Type 2 Diabetes Choose Glucose-Lowering Medications? A Qualitative Study.Journal of general internal medicine · 2026Article
- Lower Risk of Incident Dementia with SGLT2 Inhibitor Versus DPP-4 Inhibitor Initiation in Patients with Type 2 Diabetes and Prior Traumatic Brain Injury: A Retrospective Cohort Study.Drug design, development and therapy · 2026Article
- Emerging insights of decoding the genetic blueprint, molecular mechanisms, and future horizons in precision medicine for the treatment of type 2 diabetes.Journal of diabetes and metabolic disorders · 2025Review
- Cardiac Rehabilitation and Cardiovascular Prevention in Patients with Type 2 Diabetes Mellitus: From Initial Assessment to Comprehensive Management.Journal of clinical medicine · 2025Review
- Sociodemographic and biological determinants of insulin initiation in type 2 diabetes: a cohort study using routinely collected primary care data.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025Article
- Comparative disease burden of early-onset and late-onset type 2 diabetes in the U.S.: Evidence from NHANES 2003-2018.Journal of diabetes investigation · 2025Article
- Platelet-Rich Plasma for Wound Healing in Diabetic Patients.Medicina (Kaunas, Lithuania) · 2025Review
- Understanding primary care provider perspectives of the implementation of an integrated diabetes and mental health care solution.Primary health care research & development · 2025Article
- Heterogeneity of continuous glucose monitoring features and their clinical associations in a type 2 diabetes population.Diabetes, obesity & metabolism · 2025Article
- Time to Treatment Intensification with Glucagon-Like Peptide-1 Receptor Agonists Versus Comparators in People with Type 2 Diabetes Treated with Metformin.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous guidelines for the treatment of people with type 2 diabetes mellitus (T2D) have relied heavily upon rigid algorithms for the sequential addition of pharmacotherapies to achieve target glycemic control. More recent guidelines advocate a personalized approach for diabetes treatment, to improve patient satisfaction, quality of life, medication adherence and overall health outcomes. Clinicians should work with patients to develop personalized goals for their treatment, including targeted glycemic control, weight management, prevention and treatment of associated comorbidities and avoidance of complications such as hypoglycemia. Factors that affect the intensity of treatment and choice of pharmacotherapy should include medical and patient influences. Medical considerations include the diabetes phenotype, biomarkers including genetic tests, and the presence of comorbidities such as cardiovascular, renal, or hepatic disease. Patient factors include their treatment preference, age and life expectancy, diabetes duration, hypoglycemia fear and unawareness, psychological and social circumstances. The use of a personalized approach in the management of people with T2D can reduce the cost and failure associated with the algorithmic "one-size-fits-all" approach, to anticipate disease progression, improve the response to diabetes pharmacotherapy and reduce the incidence of diabetes-associated complications. Ultimately, the use of personalized medicine in people with T2D should improve medication adherence, patient satisfaction and quality of life to reduce diabetes distress and improve physical health outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.